Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-04-04
|
filgotinib |
Sjögren's syndrome |
2 |
Galapagos (Belgium) Gilead Sciences (USA - CA) |
Autoimmune diseases - Ophtalmological diseases |
2017-04-04
|
filgotinib |
ankylosing spondylitis |
2 |
Galapagos (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-04-04
|
bavituximab |
non-small-cell lung cancer (NSCLC) |
3 |
Peregrine Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2017-04-04
|
Rolontis™ (eflapegrastim) |
chemotherapy-induced neutropenia |
preclinical |
Spectrum Pharmaceuticals (USA - NV) |
Cancer - Oncology - Hematological diseases |
2017-04-04
|
bispecific small molecules |
|
preclinical |
Evotec (Germany) Exscientia (UK) |
Cancer - Oncology |
2017-04-04
|
VB-600 series |
|
preclinical |
VBL Therapeutics (Israel) |
Cancer - Oncology |
2017-04-03
|
PI-2620 |
Alzheimer's disease, Progressive Supranuclear Palsy (PSP) |
preclinical, 1 |
Piramal Imaging (India) AC Immune (Switzerland) |
Neurodegenerative diseases |
2017-04-03
|
A2A receptor antagonist |
|
preclinical |
iTeos Therapeutics (Belgium) |
Cancer - Oncology |
2017-04-03
|
SD-101 |
epidermolysis bullosa |
3 |
Amicus Therapeutics (USA - NJ) |
Rare diseases - Genetic diseases - Dermatological diseases |
2017-04-03
|
ATIR201™ |
beta-thalassemia major |
1-2 |
Kiadis Pharma (The Netherlands) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-04-03
|
514G3 |
Staphylococcus Aureus bacteremia |
1-2 |
XBiotech (USA - TX) |
Infectious diseases |
2017-04-03
|
FPA008 (cabiralizumab) |
|
preclinical |
Five Prime Therapeutics (USA - CA) |
Cancer - Oncology |
2017-04-03
|
Opdivo® (nivolumab) |
previously treated advanced non-small cell lung cancer |
1b |
BMS (USA - NY) |
Cancer - Oncology |
2017-04-03
|
Opdivo® (nivolumab) |
first recurrence of glioblastoma multiforme (GBM) |
3 |
BMS (USA - NY) |
Cancer - Oncology |
2017-04-03
|
Opdivo® (nivolumab)+Yervoy® (ipilimumab) |
previously untreated advanced melanoma |
3 |
BMS (USA - NY) |
Cancer - Oncology |
2017-04-03
|
VB-703 |
NASH (non-alcoholic steatohepatitis), liver fibrosis |
preclinical |
VBL Therapeutics (Israel) |
Liver diseases - Hepatic diseases |
2017-04-03
|
VB-201 |
NASH (non-alcoholic steatohepatitis), liver fibrosis |
preclinical |
VBL Therapeutics (Israel) |
Liver diseases - Hepatic diseases |
2017-04-03
|
ATIR101™ (Allodepleted T-cell ImmunotheRapeutics) |
acute leukemia |
3 |
Kiadis Pharma (The Netherlands) |
Cancer - Oncology |
2017-04-02
|
BeiGene-283/BGB-283 |
B-RAF or K-RAS/N-RAS mutated solid tumors, pancreatic cancer |
1b |
BeiGene (China) |
Cancer - Oncology |
2017-04-01
|
IPI-549 |
advanced solid tumors |
1-1b |
Infinity Pharmaceuticals (USA - MA) |
Cancer - Oncology |